Physician profile
Ashwin Rumalla
NPI 1790721165
$2,988.48
in general payments reported to CMS, 2019-2025
22 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $118 · 2021: $530 · 2022: $484 · 2023: $226 · 2024: $648 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.91 | 2019-2025 | Mavyret |
| Boston Scientific Corporation | $405.32 | 2022-2025 | Exalt Model D, Watchman Flx, Hydratome Rx 44 |
| Janssen Biotech, INC. | $306.07 | 2023-2025 | Tremfya, Stelara, Simponi |
| Stryker Corporation | $253.05 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $233.29 | 2019-2024 | Iqirvo |
| Lilly USA, LLC | $164.98 | 2024 | Omvoh |
| Medtronic, INC. | $154.15 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $108.02 | 2023-2025 | Dupixent |
| Celgene Corporation | $103.84 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $75.20 | 2022 | |
| Qol Medical, LLC | $70.24 | 2024 | Sucraid |
| Pfizer INC. | $67.53 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $49.52 | 2021 | |
| Genzyme Corporation | $36.18 | 2025 | |
| Phathom Pharmaceuticals, INC. | $35.71 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $34.35 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $20.56 | 2024 | Breztri |
| Vivus LLC | $19.89 | 2022 | |
| Olympus America INC. | $18.20 | 2024 | Endoclot Phs |
| Merck Sharp & Dohme LLC | $15.60 | 2019 | |
| Gilead Sciences, INC. | $13.86 | 2023 | |
| Organon LLC | $9.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Rumalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.